Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study

Abstract

The PANCOSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine (GEM) versus GEM alone in the treatment of patients with metastatic pancreatic cancer in Spain. Efficacy data were obtained from the MPACT study and were modeled to a lifetime horizon using a Markov model. The analysis was performed from the payer's perspective. Use of resources and key assumptions of the analysis were validated by a panel of oncologists. The addition of nab-paclitaxel to GEM showed higher effectiveness results (0.156 additional quality adjusted life years) at a higher cost (€6,477), resulting in a cost per quality-adjusted life years gained of €41,519. The combination of nab-paclitaxel and GEM has been shown to be an effective and well-tolerated option for the treatment of metastatic pancreatic cancer and, in addition to becoming the new standard of care, could also be considered a cost-effective option.

French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients

“…They reported that GEM-NAB is more cost-effective than GEM alone. Carrato et al 24 and Gharaibeh et al 25 reported similar results. In contrast, from the perspective of US healthcare payers, Gharaibeh et al 25 reported that GEM-NAB is less cost-effective than GEM.…”

Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan

“…Lazzaro et al 7 performed a cost-effectiveness analysis of GnP compared with G in unresectable pancreatic cancer from the perspective of Italian payers. They reported that GnP is more costeffective than G. Carrato et al 8 and Gharaibeh et al 9 reported similar results. In contrast, from the perspective of US healthcare payers, Gharaibeh et al 10 reported that GnP is less cost-effective than G.…”

“…We estimated the disutility from a previous study. 8 In addition, disutility was applied only to "survival of progression-free state. "…”

Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas

“…ABI-007 is a new polyoxyethylated castor oil-free formulation of paclitaxel developed to overcome the limitations attributed to the solvent Kolliphor EL (previously called Cremophor EL) and improve the therapeutic index and safety profile of solvent-based paclitaxel (sb-P) [ 9 ]. Peripheral neuropathy (PN) is the major toxicity related to taxanes [ 6 , 10 , 11 , 12 ]. Although it is not completely clear how taxanes cause PN, in vitro studies have demonstrated that taxanes interrupt axonal transport mediated by microtubules, leading to neuropathy [ 13 ].…”